Overview

Clinical Study of rATG Individualized Administration in Haploidentical Hematopoietic Stem Cell Transplantation

Status:
Recruiting

Trial end date:
2025-05-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this prospective, open-label, pairing design, single-center study is to evaluate the effect of individualized rATG dosing vs traditional weight-based rATG dosing regimen（10mg/kg）for patients with acute leukemia undergoing a myeloablative conditioning regimen and haploidentical hematopoietic stem cell transplantation (haplo-HSCT).

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

The First Affiliated Hospital of Soochow University

Criteria

Inclusion Criteria:

1. All patients were diagnosed with acute leukemia.

2. All patients should have the indication of Haploidentical hematopoietic stem cell
transplant and receive the myeloablative conditioning regimen.

2. All patients should sign an informed consent document indicating that they understand
the purpose of and procedures required for the study and be willing to participate in the
study.

Exclusion Criteria:

Patients with any conditions not suitable for the trial (investigators' decision).